Bio Green Med Solution, Inc.

Regulatory Filings • Aug 13, 2025

Field: Rule-Page

Field: /Rule-Page

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, DC 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

August 12, 2025

Date of Report (date of earliest event reported)

Cyclacel Pharmaceuticals, Inc.

(Exact name of Registrant as specified in its charter)

Delaware	0-50626	91-1707622
(State
or other jurisdiction of incorporation
or organization)	(Commission File
Number)	(I.R.S.
Employer Identification
Number)

Level 10, Tower 11 , Avenue 5, No. 8

Jalan Kerinchi , Kuala Lumpur , Malaysia 592000

(Address of principal executive offices) (Zip code)

(908) 517-7330

(Registrant’s telephone number, including area code)

Not Applicable

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

| ☐ | Written
communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| --- | --- |
| ☐ | Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| ☐ | Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| ☐ | Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |

Securities registered pursuant to Section 12(b) of the Act:

| Title
of each class | Trading
Symbol(s) | Name
of each exchange on which registered |
| --- | --- | --- |
| Common
Stock, par value $0.001 per share | CYCC | The Nasdaq Capital Market |
| Preferred
Stock, $0.001 par value | CYCCP | The Nasdaq Capital Market |

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Field: Rule-Page

Field: /Rule-Page

Field: Page; Sequence: 1

Field: /Page

Item 9.01. Financial Statements and Exhibits.

In reference to meeting the eligibility requirements under General Instructions I.A.4 of the registration statement on Form S-3, Cyclacel Pharmaceuticals, Inc., a Delaware corporation is presenting its audited consolidated financial statements for the quarter ended March 31, 2025, including the notes to such financial statements.

(d) Exhibits.

| Exhibit
No. | Exhibit |
| --- | --- |
| 99.1 | Audited Financial Statements for the quarter ended March 31, 2025 |
| 104 | Cover
Page Interactive Data File (embedded within the XBRL document) |

Field: Page; Sequence: 2; Options: NewSection; Value: 2

2

Field: /Page

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

| Date:
August 12, 2025 | |
| --- | --- |
| By: | /s/
Datuk Dr. Doris Wong Sing Ee |
| Name: | Datuk
Dr. Doris Wong Sing Ee |
| Title: | Chief
Executive Officer and Executive Director |

Field: Page; Sequence: 3; Options: Last

3

Field: /Page

Field: Set; Name: xdx; ID: xdx_08B_extensions eJx1kd9KwzAUh5+g73AoXo4uKUykd1rmEDcp3RjexvZMw9qccpLO7ZF8S9PUzhsNgZDk950vf+J4Fq/oUTfI8PpQrmGHbdcoh1DiARlNhT6RPz1n4McS37V1rIwL0wnMyTPomdtEKr8ekidtsc5A3M1lOk8XIEUmFlBs4mjYz8kcdI3GadWAMjUUTB1rdIovY4WdOpOh9hJMe2SryWQgEzFuf0EqZAovdFKfxEcL63UeR7PQonjF1Hc+tTw7NAMJywZbr7Mj/dvDaareOmqzgoc7M9ZbR9VRJELIQvFeNT1usH1D9lEp0lSK+59TXAkIyAxuAgWdYjgN3B8W/1otmZCfqo8q5O2H4v9UIzZ5roKr0f+DHfDJ+A2iDIry